Learn About Spastic Paraplegia Type 7

What is the definition of Spastic Paraplegia Type 7?

Spastic paraplegia type 7 (also called SPG7) is one of more than 80 genetic disorders known as hereditary spastic paraplegias. These disorders primarily affect the brain and spinal cord (central nervous system), specifically nerve cells (neurons) that extend down the spinal cord. These neurons are used for muscle movement and sensation. Signs and symptoms of hereditary spastic paraplegias are characterized by progressive muscle stiffness (spasticity) in the legs and difficulty walking.

Save information for later
Sign Up
What are the causes of Spastic Paraplegia Type 7?

Mutations in the SPG7 gene cause spastic paraplegia type 7. The SPG7 gene provides instructions for producing a protein called paraplegin. Located within the inner membrane of the energy-producing centers of cells (mitochondria), paraplegin is one of the proteins that form a complex called the m-AAA protease. The m-AAA protease acts as an enzyme and is responsible for assembling ribosomes (cellular structures that process the cell's genetic instructions to create proteins) and removing nonfunctional proteins in the mitochondria.

How prevalent is Spastic Paraplegia Type 7?

The prevalence of all hereditary spastic paraplegias combined is estimated to be 2 to 6 in 100,000 people worldwide. This group of conditions is the most common cause of inherited spasticity. Spastic paraplegia type 7 likely accounts for only a small percentage of all spastic paraplegia cases.

Is Spastic Paraplegia Type 7 an inherited disorder?

In most cases, spastic paraplegia type 7 is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Spastic Paraplegia Type 7 Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Spastic Paraplegia Type 7 Clinical Trials?
Effects of Spinal Cord Stimulation Therapy on Motor Function and Gait in Patients With Pure Hereditary Spastic Paraplegias

Summary: It's a single-center, prospective, open label clinical study with a 12 months follow-up period, to investigate the therapeutic effect and safety of spinal cord stimulation (SCS) on motor function and gait in patients with pure Hereditary Spastic Paraplegias.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Investigating the Genetic Basis of Hereditary Spastic Paraplegia

Summary: The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined pr...

Who are the sources who wrote this article ?

Published Date: June 25, 2021Published By: National Institutes of Health